Compare VFF & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFF | JSPR |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.2M | 14.9M |
| IPO Year | 2013 | N/A |
| Metric | VFF | JSPR |
|---|---|---|
| Price | $2.00 | $0.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.0M | 732.4K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 184.38 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $215,937,000.00 | N/A |
| Revenue This Year | $12.19 | N/A |
| Revenue Next Year | $15.82 | N/A |
| P/E Ratio | $99.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $0.32 |
| 52 Week High | $4.99 | $3.29 |
| Indicator | VFF | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 59.08 |
| Support Level | $1.81 | $0.62 |
| Resistance Level | $2.11 | $1.06 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 45.26 | 52.74 |
Village Farms International Inc owns and operates intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells tomatoes, bell peppers and cucumbers. Its wholly owned subsidiary, Pure Sunfarms, is a vertically integrated licensed producer and supplier of cannabis products sold to other licensed providers and provincial governments across Canada and internationally. The Company's wholly owned subsidiary, Balanced Health, develops and sells, cannabidiol (CBD) based products including ingestible, edible and topical applications. The operating segments of the Company are VF Fresh (Produce), Cannabis Canada, Cannabis U.S., Clean Energy, and Cannabis - Netherlands. The company makes majority of its revenue from the Cannabis Canada segment.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.